VYNE Therapeutics (NASDAQ:VYNE) Posts Earnings Results, Misses Expectations By $3.33 EPS

VYNE Therapeutics (NASDAQ:VYNE) announced its quarterly earnings data on Thursday. The company reported ($3.51) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($3.33), FiscalAI reports. The business had revenue of $0.10 million during the quarter, compared to analysts’ expectations of $0.20 million. VYNE Therapeutics had a negative net margin of 4,726.21% and a negative return on equity of 70.42%.

VYNE Therapeutics Stock Performance

Shares of VYNE Therapeutics stock traded down $0.23 during midday trading on Thursday, hitting $28.32. The company had a trading volume of 93,278 shares, compared to its average volume of 44,151. The stock has a market capitalization of $18.98 million, a P/E ratio of -74.54 and a beta of 2.00. The company has a 50 day moving average of $32.72 and a 200 day moving average of $31.48. VYNE Therapeutics has a 52-week low of $14.03 and a 52-week high of $79.75.

VYNE Therapeutics Announces Dividend

The business also recently declared a special dividend, which was paid on Thursday, July 23rd. Investors of record on Wednesday, July 22nd were paid a $19.00 dividend.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of VYNE Therapeutics in a report on Monday, May 4th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has a consensus rating of “Sell”.

Institutional Investors Weigh In On VYNE Therapeutics

Several hedge funds have recently added to or reduced their stakes in VYNE. XTX Topco Ltd bought a new stake in VYNE Therapeutics during the 4th quarter valued at about $46,000. Geode Capital Management LLC lifted its stake in shares of VYNE Therapeutics by 64.2% in the fourth quarter. Geode Capital Management LLC now owns 225,152 shares of the company’s stock worth $131,000 after buying an additional 88,030 shares in the last quarter. Boothbay Fund Management LLC bought a new position in shares of VYNE Therapeutics in the second quarter worth approximately $176,000. Jane Street Group LLC purchased a new stake in shares of VYNE Therapeutics during the second quarter valued at approximately $206,000. Finally, Two Sigma Investments LP purchased a new stake in shares of VYNE Therapeutics during the third quarter valued at approximately $74,000. 83.78% of the stock is owned by institutional investors.

About VYNE Therapeutics

VYNE Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for vascular, inflammatory and fibrotic diseases. The company is advancing a pipeline of selective oral inhibitors that modulate key pathways implicated in chronic tissue damage and immune dysregulation. Headquartered in the San Francisco Bay Area, VYNE Therapeutics seeks to address high-unmet-need conditions by leveraging proprietary chemical and biological insights to create differentiated drug candidates.

The company’s lead program, VTX-002, targets the colony-stimulating factor-1 receptor (CSF-1R) pathway, which plays a central role in macrophage proliferation and activation.